P-217A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2. (2nd July 2019)

Record Type:: Journal Article
Title:: P-217A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2. (2nd July 2019)
Main Title:: P-217A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2
Authors:: Knox, J
Cheng, A
Cleary, S
Galle, P
Kokudo, N
Lencioni, R
Park, J
Zhou, J
Mann, H
Morgan, S
Liu, X
Chin, S
Vlahovic, G
Fan, J
Abstract:
Is Part Of:: Annals of oncology. Volume 30(2019)Supplement 4
Journal:: Annals of oncology
Issue:: Volume 30(2019)Supplement 4
Issue Display:: Volume 30, Issue 4 (2019)
Year:: 2019
Volume:: 30
Issue:: 4
Issue Sort Value:: 2019-0030-0004-0000
Page Start:
Page End:
Publication Date:: 2019-07-02
Subjects:: Oncology -- Periodicals
616.992
Journal URLs:: https://www.journals.elsevier.com/annals-of-oncology ↗
http://ukcatalogue.oup.com/ ↗
DOI:: 10.1093/annonc/mdz155.216 ↗
Languages:: English
ISSNs:: 0923-7534
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 1043.320000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 12154.xml